TradingMenu expanded
Forge Markets Forge Pro Browse Companies
DataMenu expanded
Forge Data Private Market Index Forge Accuidity Index IPO Stock Tracker
SolutionsMenu expanded
For Institutions For Shareholders For Investors For Companies
InsightsMenu expanded
All Insights Blog Glossary Reports Videos Webinars
Popular Topics
Buying Pre-IPO Shares Selling Pre-IPO Shares Private Market Updates Forge Investment Outlook Startup News Tech IPO Calendar for 2024
AboutMenu expanded
About Us Team Investor Relations People & Culture Careers FAQs
Log In Sign Up
Trading Menu expandedTrading
Forge Markets
Forge Pro
Browse Companies
Data Menu expandedData
Forge Data
Private Market Index
Forge Accuidity Index
IPO Stock Tracker
Solutions Menu expandedSolutions
For Institutions
For Shareholders
For Investors
For Companies
Insights Menu expandedInsights
All Insights
Blog
Glossary
Reports
Videos
Webinars
Popular Topics
Buying Pre-IPO Shares
Selling Pre-IPO Shares
Private Market Updates
Forge Investment Outlook
Startup News
Tech IPO Calendar for 2024
About Menu expandedAbout
About Us
Team
Investor Relations
People & Culture
Careers
FAQs
Trading / Browse Private Companies / ArteraAI Stock

ArteraAI Stock

artera.aiHealthcare / BioTech & PharmaFounded: 2021Funding to Date: $89.5MM

Artera, founded in 2021, is a precision medicine company and the developer of multimodal artificial intelligence-based predictive and prognostic tests with the goal of personalizing therapy for cancer patients. Artera’s flagship test is the ArteraAI Prostate Test, seeking to predict therapy benefit in localized prostate cancer. Artera is headquartered in Los Altos, California.

Buy or sell ArteraAI stockLearn more about ArteraAI IPO

Register To Buy and Sell Shares

For more details on financing and valuation for ArteraAI, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value

Powered by Forge Data

Access ArteraAI’s valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like ArteraAI.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.

Register

Animation displayed is not current and securities are shown for illustrative purposes only.

ArteraAI investors also invested in these private companies

Koch Disruptive Technologies
Coatue Management
Breyer Capital
Time Ventures
Johnson & Johnson Innovation
FactoryHQ
Walden Catalyst

Team

Management Team

Andre Esteva Ph.D
Co-Founder, Chief Executive Officer & Board Member

Frequently Asked Questions About ArteraAI’s Stock

plusminus
Can you buy ArteraAI’s stock?
ArteraAI is not publicly traded on NYSE or NASDAQ in the U.S. To buy ArteraAI’s stock you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.
plusminus
Can you sell ArteraAI’s stock?
Yes, you can sell stock of a private company like ArteraAI. Forge can help you sell your ArteraAI stock in a way that works for you and the company. So if you are seeking liquidity, register with us today to get started.
plusminus
What is ArteraAI’s stock price?
ArteraAI is a privately held company and therefore does not have a public stock price. However, you may access ArteraAI’s private market stock price with Forge Data.
plusminus
What is ArteraAI’s stock ticker symbol?
ArteraAI does not have an official ticker symbol because this company is not currently publicly traded.
plusminus
Can institutional investors buy and sell private market stocks?
Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

Other companies like ArteraAI in the BioTech & Pharma sector

Egenesis

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$387.57MM

Colossal Biosciences

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$1.01B

Prime Medicine

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$1.23B

ADARx Pharmaceuticals

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$827.77MM

Altos Labs

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$6.33B

Tempus

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$8.7B

Pendulum Therapeutics

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$308.05MM

Cytonics

Sector
Healthcare / BioTech & Pharma
 
 

AI Therapeutics

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$110MM

News Highlights

Fierce Healthcare 06/21/2023
Tech company Artera launches solution to help health systems manage all those texts, emails to patients
Health systems have made big investments in the past few years to build out "digital front doors" for patients. But in many cases, all these "doors" lead down different hallways, resulting in a fragmented, disjointed experience for patients. All these communication tools also cause headaches for healthcare staff to manage.
Axios 03/21/2023
Artera snags $90M for prostate cancer test
Artera, a medical company developing AI tests to personalize therapy for cancer patients, raised $90 million, the company tells Axios exclusively.
Crunchbase 03/21/2023
Cancer-Testing Startup Artera Raises $90M
Artera, which uses artificial intelligence for cancer testing and personalized care, raised a $90 million round to support the distribution of its flagship test in prostate cancer.

Trending Companies

Frequently Asked Questions

Updated on: Apr 27, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.